Back to search results

Study of IgPro20 for Multiple Myeloma and Hypogammaglobulinemia

This study is looking at whether a drug called IgPro20 can help prevent infections in people with multiple myeloma (a type of blood cancer) who also have hypogammaglobulinemia (low levels of infection-fighting proteins). These patients are currently receiving a specific type of treatment called bispecific antibodies. You may be able to join if you are 18 or older, have multiple myeloma, and have received 1 to 4 cycles of bispecific antibody treatment. The study aims to enroll about 100 people and will measure the difference in overall infection rates after 6 months between those receiving IgPro20 and those receiving standard care. The current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 100 participants. It is not specified if it is randomized or blinded.
What's involved
IgPro20 will be given under the skin using an infusion pump, in addition to your standard care treatment. The study will measure infection rates over 6 months.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint measures infection rates at 6 months, suggesting follow-up for at least this duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06976476

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Recruiting
PHASE2Ages 18+InterventionalTreatment
Memorial Sloan Kettering Cancer Center
~100 participants
Updated 2026-03-11 on ClinicalTrials.gov
What's tested:IgPro20

At a glance

Recruiting sites
7 of 8 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Difference in overall infection rates between Standard of Care participants and participants receiving IgPro20
Measured over 6 months

Conditions

Multiple Myeloma
Hypogammaglobulinemia
Hypogammaglobulinemia, Acquired

Explore related trials

HypogammaglobulinemiaMultiple Myeloma

Where it's being run

8 sites across 2 states
New York5
New Jersey3

Study leadership

  • Zainab Shahid, MBBS · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Zainab Shahid, MBBS
[email protected]
212-639-6483
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of RRMM receiving a commercially available bispecific antibody
Received at least 1 but no more than 4 cycles of BsAb
Males or females greater than or equal to 18 years old at the time of consent
ECOG ≤ 3
Life expectancy \> 12 months

Exclusion

HSCT within 3 months before enrollment
Planned CAR-T therapy in the next 6 months
\>1 major (deep-seated) infection within the preceding 3 months
HIV infection, Active HCV, or Active HBV infection
Pregnancy
Neutrophils \< 500 x 10\^9 per mL, Platelets \< 30 x 10\^9 per mL
History of cancer other than MM in the last 3 years requiring active chemotherapy or radiation
Known reaction/allergy to IgG products
Intracranial hemorrhage or embolic CVA in the last 6 months
Hyperproteinemia
Protein-losing enteropathy
Creatinine Cl \<30 ml/min
Documented progression on BsAb
Known history of Hyperprolinemia
On current or previous IVIG (in the last 3 months)

What this trial measures

  • Difference in overall infection rates between Standard of Care participants and participants receiving IgPro206 months

    To compare overall infection rates amongst (RR) multiple myeloma patients with hypogammaglobulinemia receiving subcutaneous immunoglobulin (IgPro20) to those in observational arm over a 6-month period.